ONLINE Webinar: Health Canada – Psychedelic Restricted Drugs: Legal Access Pathways
MARK YOUR CALENDARS for Thursday, August 18, 2022; 1:00 pm - 2:00 pm EDT, and share this news with your colleagues!
Topic: Health Canada – Psychedelic Restricted Drugs: Legal Access Pathways.
Description: This is an open discussion webinar that will provide an overview of how psychedelic drugs are regulated in Canada and an explanation of the three legal pathways to access:
1. Clinical trials;
2. Special Access Program; and
3. Individual subsection 56(1) exemptions from the Controlled Drugs and Substances Act.
The presentation will include information about Health Canada’s clinical trial application process and the Special Access Program requirements, providing clarification on the process to apply, who can apply, and under what circumstances.
Questions from the moderator will be posed to the speakers to facilitate discussion. There will be time for audience questions.
Speaker: Dr. Jennifer Pelley, Director of the Office of Legislative and Regulatory Affairs, Controlled Substances Directorate, Health Canada
Speaker: Dr. Daniel Keene, Associate Director of the Office of Clinical Trials at the Pharmaceutical Drug Directorate at Health Canada
Registration Deadline: Tuesday, August 16, 2022, 4 pm EDT
*Registrants may be substituted, but no refunds will be issued after the deadline.
*Disclaimer: CAPRA reserves the right to make amendments to the conference (including but not limited to speakers' identity, topics, locations, the timing of speakers) without notice to you. If the conference is cancelled for any reason whatsoever, such reason not within the control of CAPRA, CAPRA shall not be liable for any cost or loss otherwise incurred.
**Update: This webinar will be hosted using Go To Webinar.**
Event Registration Form: Please add your First name, Last name and the Email address you will use to log in on the day of the Webinar.
Registered attendees will receive an official Go To Webinar link to join the Webinar after the Registration deadline.
Check system requirements to avoid connection issues on the day of the event.
In case of unexpected interruptions such as a power outage, please log back, and the Webinar will restart from where it was disconnected.
Speakers / Panelists
-
Dr. Daniel Keene
Associate Director of the Office of Clinical Trials at the Pharmaceutical Drug Directorate at Health Canada
Dr. Daniel Keene
Associate Director of the Office of Clinical Trials at the Pharmaceutical Drug Directorate at Health Canada
Health Canada
After obtaining his medical degree from the University of Saskatchewan, Dr. Daniel Keene completed his post-graduate medical training in pediatrics at the Hospital for Sick Children in Toronto, and neurology at the Montreal Neurological Institute. He is a fellow of the Royal College of Physicians and Surgeons of Canada with speciality certification in both pediatrics and neurology. He obtained a Master of Arts in Public Policy from Carleton University and a Graduate Certificate in Academic Excellence in Epidemiology form the School of Public Health, University of Michigan. Prior to coming to Health Canada, he was an active member of the Medical Faculty at the University Ottawa in the Departments of Pediatrics and Medicine, and Senior Clinical Investigator at the Children’s Hospital of Eastern Ontario. He has authored over a 100-peer reviewed scientific articles and contributed to several sentinel medical textbooks on a variety of topics including identification of pediatric neurological disorders, neuro-oncology, epidemiology and health policy.
-
Dr. Jennifer Pelley
Director of the Office of Legislative and Regulatory Affairs, Controlled Substances Directorate, Health Canada
Dr. Jennifer Pelley
Director of the Office of Legislative and Regulatory Affairs, Controlled Substances Directorate, Health Canada
Health Canada
Dr. Jennifer Pelley is the Director of the Office of Legislative and Regulatory Affairs in Health Canada’s Controlled Substances Directorate. Jennifer has worked at Health Canada in various roles since 2009, and has been supporting the development and implementation of legislation and regulations since 2016.
From 2016 to 2019, Jennifer was a manager on the team responsible for developing regulations to support the legalization and regulation of cannabis in Canada. She has worked in the Controlled Substances Directorate since 2019, where she has led a number of regulatory files, including the ongoing modernization of regulations for controlled substances and regulatory changes that restored access to restricted drugs through the Special Access Program.
A scientist by training, Jennifer holds a Ph.D. in Biochemistry and Molecular Biology from the University of Calgary and a B.Sc. in Biochemistry from Queen’s University.
Registration is now closed